Abstract
In the United States (US), COPD imposes a substantial societal health and economic burden. High prices of inhalers, the mainstay treatment, due to patent protection and limited generic availability, can lead to high out-of-pocket (OOP) costs. This study aims to model one-year economic burden of market exclusivity for inhaled corticosteroids (ICS) combined with long-acting beta2 agonists (LABA) among end-stage COPD patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
